Chris N Barnes Selected Research

Muscarinic Antagonists

5/2020	Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
1/2020	Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
10/2019	Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
10/2019	Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.
10/2019	Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease.
4/2019	Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.
1/2019	Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
1/2019	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
1/2019	Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
11/2017	A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chris N Barnes Research Topics

Disease

13	Chronic Obstructive Pulmonary Disease (COPD) 12/2020 - 11/2017
2	Gastroparesis 01/2023 - 01/2021
1	Congenital Adrenal Hyperplasia (Hyperplasia, Congenital Adrenal) 10/2021
1	Congenital adrenal hyperplasia due to 21 hydroxylase deficiency 10/2021
1	Diarrhea 01/2021
1	Critical Illness (Critically Ill) 01/2021
1	Infections 12/2019
1	Ventilator-Associated Pneumonia 09/2019
1	Healthcare-Associated Pneumonia 09/2019
1	Atrial Fibrillation 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2019

Drug/Important Bio-Agent (IBA)

13	revefenacinIBA 12/2020 - 11/2017
10	Muscarinic AntagonistsIBA 05/2020 - 11/2017
5	Bronchodilator Agents (Bronchodilators)IBA 05/2020 - 01/2019
4	Tiotropium Bromide (Spiriva)FDA Link 10/2019 - 01/2019
3	SolutionsIBA 12/2020 - 01/2019
2	TD-5108IBA 01/2023 - 01/2021
2	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 01/2021
2	Cholinergic Antagonists (Anticholinergics)IBA 12/2020 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2020 - 01/2020
2	telavancin FDA Link 12/2019 - 09/2019
1	Serotonin 5-HT4 Receptor AgonistsIBA 01/2023
1	GlucocorticoidsIBA 10/2021
1	Metoclopramide (Reglan)FDA LinkGeneric 01/2021
1	GoldIBA 05/2020
1	Formoterol Fumarate (Oxis)FDA Link 04/2020
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2020
1	Therapeutic UsesIBA 10/2019
1	PowdersIBA 10/2019
1	Vancomycin FDA LinkGeneric 09/2019
1	omega-Chloroacetophenone (Mace)IBA 01/2019

Therapy/Procedure

5	Therapeutics 05/2020 - 01/2019
2	Nebulizers and Vaporizers (Inhaler) 05/2020 - 04/2020
1	Enteral Nutrition (Feeding, Tube) 01/2021
1	Dry Powder Inhalers 10/2019